Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

Reuters

Sun, May 11, 2025, 3:06 PM 1 min read

(Reuters) -Eli Lilly said connected Sunday its cause Zepbound was superior to Novo Nordisk's Wegovy crossed 5 weight-loss targets specified arsenic reducing waist circumference, citing information from a head-to-head trial.

Lilly reported successful December that its obesity cause had already met the main goal, starring to 47% much value nonaccomplishment than those who received Wegovy. Full information from the survey was reported by the institution successful a property merchandise and presented astatine the European Congress connected Obesity.

The information is the archetypal head-to-head proceedings comparing the wildly fashionable medicines, and gives Lilly much firepower arsenic it seeks to summation wider security sum successful an obesity cause marketplace estimated to scope much than $150 cardinal annually by the adjacent decade.

It comes days aft CVS Health's determination to driblet Zepbound from immoderate lists of medicines it covers for reimbursement, alternatively favoring Wegovy.

Zepbound helped astir 25% much participants suffer much than 15% of their value compared to Wegovy, Lilly said connected Sunday.

The proceedings besides showed that attraction with Zepbound achieved a superior mean waist circumference simplification of 18.4 centimeters (cm), portion those treated with Wegovy saw an mean simplification of 13 cm.

While Lilly's cause mimics 2 gut hormones to assistance trim weight, Wegovy has a azygous mode of action.

U.S. approvals for Zepbound and Wegovy were based connected abstracted trials successful which Lilly's cause helped patients suffer much than 22% of their value aft 72 weeks, portion Wegovy led to 15% value nonaccomplishment aft 68 weeks.

(Reporting by Christy Santhosh successful Bengaluru; Editing by Leroy Leo)